Medican Enterprises Stock Performance
| MDCN Stock | USD 0.0001 0.00 0.00% |
Medican Enterprises holds a performance score of 16 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 39.96, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Medican Enterprises will likely underperform. Use Medican Enterprises information ratio, as well as the relationship between the kurtosis and day typical price , to analyze future returns on Medican Enterprises.
Risk-Adjusted Performance
16 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Medican Enterprises are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent fundamental indicators, Medican Enterprises displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Medican |
Medican Enterprises Relative Risk vs. Return Landscape
If you would invest 0.00 in Medican Enterprises on November 3, 2024 and sell it today you would earn a total of 0.01 from holding Medican Enterprises or generate 9.223372036854776E16% return on investment over 90 days. Medican Enterprises is currently generating 45.9016% in daily expected returns and assumes 219.5251% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Medican, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Medican Enterprises Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medican Enterprises' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Medican Enterprises, and traders can use it to determine the average amount a Medican Enterprises' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2091
| Best Portfolio | Best Equity | MDCN | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 219.53 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.21 actual daily | 16 84% of assets perform better |
Based on monthly moving average Medican Enterprises is performing at about 16% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medican Enterprises by adding it to a well-diversified portfolio.
Medican Enterprises Fundamentals Growth
Medican Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Medican Enterprises, and Medican Enterprises fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medican Pink Sheet performance.
| Return On Asset | -68.18 | |||
| Current Valuation | 7.77 M | |||
| Shares Outstanding | 134.8 M | |||
| Price To Sales | 2.72 X | |||
| Cash And Equivalents | 9.4 K | |||
| Book Value Per Share | (2.42) X | |||
| Cash Flow From Operations | (2.98 M) | |||
| Earnings Per Share | (17.92) X | |||
| Total Asset | 112.62 K | |||
| Retained Earnings | (166.24 M) | |||
| Current Asset | 74 K | |||
| Current Liabilities | 9.74 M | |||
About Medican Enterprises Performance
By examining Medican Enterprises' fundamental ratios, stakeholders can obtain critical insights into Medican Enterprises' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Medican Enterprises is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Medican Enterprises, Inc., a bio-pharmaceutical company, focuses on pursuing business opportunities in the medical and recreational marijuana sector. Medican Enterprises, Inc. was founded in 1988 and is headquartered in Las Vegas, Nevada. Medican Enterprises operates under Real Estate Services classification in the United States and is traded on OTC Exchange. It employs 3 people.Things to note about Medican Enterprises performance evaluation
Checking the ongoing alerts about Medican Enterprises for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Medican Enterprises help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medican Enterprises is way too risky over 90 days horizon | |
| Medican Enterprises has some characteristics of a very speculative penny stock | |
| Medican Enterprises appears to be risky and price may revert if volatility continues | |
| Medican Enterprises has high likelihood to experience some financial distress in the next 2 years | |
| The company has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Medican Enterprises until it has trouble settling it off, either with new capital or with free cash flow. So, Medican Enterprises' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medican Enterprises sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medican to invest in growth at high rates of return. When we think about Medican Enterprises' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (56.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Medican Enterprises currently holds about 9.4 K in cash with (2.98 M) of positive cash flow from operations. |
- Analyzing Medican Enterprises' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medican Enterprises' stock is overvalued or undervalued compared to its peers.
- Examining Medican Enterprises' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medican Enterprises' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medican Enterprises' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medican Enterprises' pink sheet. These opinions can provide insight into Medican Enterprises' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Medican Pink Sheet
Medican Enterprises financial ratios help investors to determine whether Medican Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medican with respect to the benefits of owning Medican Enterprises security.